After studying Mesotherapy with renowned practitioners in Paris, Dr. Lionel Bissoon? introduced Mesotherapy to the United States in the late 1990s. Thanks to the success of his practice and his continuing education efforts, Dr. Bissoon is promoting the latest Mesotherapy procedures across the nation. Nearly all certified Mesotherapists in the United States practice techniques pioneered by Dr. Bissoon.
Member, French Society of Mesotherapy
Chairman, Bissoon Institute of Mesotherapy
Pioneered by the French physician Dr. Michel Pistor in 1952, Mesotherapy is a minimally invasive procedure that is widely used in Europe and elsewhere to treat various injuries and medical conditions. This medical specialty targets problem areas with microinjections of conventional or homeopathic medicines, vitamins, minerals and amino acids. Tiny "medicinal bullets" are delivered directly into the mesoderm (middle layer of skin) that are highly specific to the condition being treated. Among its many applications, Mesotherapy can be used for the following:
A dog that is potentially a candidate for long-term use of carprofen should have a complete examination by the veterinarian, a screening blood panel to establish baseline biochemical values, and ideally some kind of recheck testing two weeks after starting carprofen. This is because most adverse reactions, unusual as they may be, occur within this initial time frame and it is important that they be recognized before they get out of hand. After this initial period, complete blood panels should be screened every 6 months, an important step with any medication for long term use, not just the NSAIDs.
Mefloquine is a chiral molecule with two asymmetric carbon centres, which means it has four different stereoisomers . The drug is currently manufactured and sold as a racemate of the ( R , S )- and ( S , R )-enantiomers by Hoffman-LaRoche , a Swiss pharmaceutical company. Essentially, it is two drugs in one. Plasma concentrations of the (–)-enantiomer are significantly higher than those for the (+)-enantiomer, and the pharmacokinetics between the two enantiomers are significantly different. The (+)-enantiomer has a shorter half-life than the (–)-enantiomer.